MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN

Journal of Clinical Oncology

Volumn 18, Issue 21, 2000, Pages 3604-3613

  Cohn, Susan L ^a   London, Wendy B ^a   Huang, Donghui ^a   Katzenstein, Howard M ^a   Salwen, Helen R ^a   Reinhart, Todd ^a   Madafiglio, Janice ^a   Marshall, Glenn M ^a   Norris, Murray D ^a   Haber, Michelle ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; TENIPOSIDE;

ARTICLE; CANCER SURVIVAL; DIAGNOSTIC VALUE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034327928     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.21.3604     Document Type: Article

References (62)

1. Neuroblastoma, its natural history and prognosis: A study of 487 cases
2. A proposed staging for children with neuroblastoma. Children's Cancer Study Group A
3. Neuroblastoma
4. Localized neuroblastoma treated by surgery: A Pediatric Oncology Group study
5. Natural history and biology of stage A neuroblastoma: A Pediatric Oncology Group study
6. Biological variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A Children's Cancer Group study
7. Localized resectable neuroblastoma: Results of the second study of the Italian Cooperative Group for Neuroblastoma
8. Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group study
9. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study
10. Disseminated neuroblastoma (stage IV and IV-S) in the first year of life: Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma
11. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup?
12. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
13. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
14. Significance of chromosome 1p loss of heterozygosity in neuroblastoma
15. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma
16. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma
17. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study
18. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma
19. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas
20. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas
21. The International Neuroblastoma Pathology Classification (the Shimada System)
22. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: Evidence for induction of autocrine growth factor activity
23. Altered growth and phenotype in clonal mycN transfectants of the SK-N-SH neuroblastoma cell line
24. The biologic effects of antisense N-myc expression in human neuroblastoma
25. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line
26. Targeted expression of MYCN causes neuroblastoma in transgenic mice
27. MYCN protein expression as a predictor of neuroblastoma prognosis
28. Immunohistochemical analysis of N-myc protein expression in neuroblastoma: Correlation with prognosis of patients
29. Amplification and expression of the N-myc gene in neuroblastoma
30. myc gene amplification and expression in primary human neuroblastoma
31. N-myc oncogene RNA expression in neuroblastoma
32. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene
33. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma
34. Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma
35. Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: A Pediatric Oncology Group study
36. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: Results from the Pediatric Oncology Group
37. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study
38. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma
39. Detection of N-myc gene amplification by fluorescence in situ hybridization: Diagnostic utility for neuroblastoma
40. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma
41. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma
42. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheet: Procedure and some applications
43. Identification and characterization of the N-myc gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities
44. Nonparametric estimation from incomplete observations
45. Regression models and life-tables
46. Amplification of cellular oncogenes: A predictor of clinical outcome in human cancer
47. Activated expression of the N-myc gene in human neuroblastomas and related tumors
48. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma
49. Increased N-myc expression following progressive growth of human neuroblastoma
50. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification
51. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: A Pediatric Oncology Group study
52. International neuroblastoma staging system stage 1 neuroblastoma: A prospective study and literature review
53. Stage IV neuroblastoma in infants: Long-term survival
54. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
55. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas
56. Prognostic factors in neuroblastoma
57. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay
58. Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene
59. c-myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways
60. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prochymosin and ornithine decarboxylase and accelerates progression into S phase early after mitogenic stimulation of quiescent cells
61. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes
62. MycN sensitizes neuroblastoma cells for drug-induced apoptosis